To the full analysis
Viridian Therapeutics stock: growth
VRDNViridian Therapeutics reported $70.85M in revenue for fiscal 2025, up 23,359.9% on the prior year, up 132.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
23.8%
per year from 2012 to 2025, per share −22.7%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2012 | |
|---|---|---|---|
| Revenue | 132.2% | 39.5% | 23.8% |
| Revenue per share | 23.1% | −15.9% | −22.7% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2012 | $4.41M | −$7.21M | −$6.33M |
| 2013 | $4.32M | −$2.16M | −$1.17M |
| 2014 | $4.32M | −$7.89M | −$2.48M |
| 2015 | $2.54M | −$11.33M | −$7.02M |
| 2016 | $3.34M | −$12.67M | −$7.23M |
| 2017 | $4M | −$26.51M | −$28.41M |
| 2018 | $8.39M | −$32.7M | −$27.29M |
| 2019 | $4.46M | −$41.87M | −$36.14M |
| 2020 | $1.05M | −$110.72M | −$29.82M |
| 2021 | $2.96M | −$79.41M | −$54.92M |
| 2022 | $1.77M | −$129.87M | −$94.64M |
| 2023 | $314K | −$237.73M | −$185.07M |
| 2024 | $302K | −$269.95M | −$232.83M |
| 2025 | $70.85M | −$342.6M | −$276.89M |
Revenue by segment
How Viridian Therapeutics, Inc. makes its money and how that has shifted. Names are as the company reports them.
- License$70.0M99%
- Collaboration$849.0K1%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| License | $70M | 98.8% |
| Collaboration | $849K | 1.2% |
| Total revenue | $70.85M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2015)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.